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Abstract  
Genetic polymorphisms are associated with breast cancer risk. Clinical and epidemiological 
observations suggest that clinical characteristics of breast cancer, such as estrogen receptor 
or HER2 status, are also influenced by hereditary factors. To identify genetic variants 
associated with pathological characteristics of breast cancer patients, a Genome Wide 
Association Study was performed in a cohort of 9365 women from the French nationwide 
SIGNAL/PHARE studies (NCT00381901/RECF1098). Strong association between the FGFR2 
locus and ER status of breast cancer patients was observed (ER-positive n=6211, ER-
negative n=2516; rs3135718 OR=1.34 p=5.46x10-12). This association was limited to 
patients with HER2-negative tumors (ER-positive n=4267, ER-negative n=1185; rs3135724 
OR=1.85 p=1.16x10-11). The FGFR2 locus is known to be associated with breast cancer risk. 
This study provides sound evidence for an association between variants in the FGFR2 locus 
and ER status among breast cancer patients, particularly among patients with HER2-
negative disease. This refinement of the association between FGFR2 variants and ER-status 
to HER2-negative disease provides novel insight to potential biological and clinical 
influence of genetic polymorphisms on breast tumors.  
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Introduction  
Since the completion of the Human Genome Project, the Genome Wide Association Scan 
(GWAS) has become the tool of choice for the detection of associations between disease risk, 
and common genetic variation. The first breast cancer risk variants identified in the GWAS 
era were in the FGFR2 locus [1,2]. 
Further analyses, mainly in case-control and prospective cohorts, have reinforced this 
association as well as identified over 90 additional breast cancer risk loci [3]. GWAS studies 
with cases selected based on the estrogen receptor (ER) status of their tumors, and control 
subjects not affected by breast cancer, have shown divergent associations between ER+ and 
ER- tumors. In these analyses, variants in FGFR2are more strongly associated with ER+ 
disease [4-14], as opposed to ER- disease, when comparing cases to healthy controls.Few 
single studies, however, have sufficient detail or sample size to carry out case-only analyses 
to further explore the relationship between genetic variants and disease characteristics, 
particularly with respect to amplification of the HER2 gene.Therefore analyses by subtype 
are often secondary, based on findings of the primary analyses of overall breast cancer risk. 
Furthermore, these studies are now carried out in large consortia with the potential for 
heterogeneity in definitions of various case characteristics, particularly ER and HER2 status. 
For example, Broeks et al. [13] examined the association between low penetrance breast 
cancer loci and specific breast tumor subtypes in the context of the Breast Cancer 
Association Consortium  (BCAC). rs2981582 in the FGFR2 locus was significantly associated 
with ER+/PR+/HER2- breast cancer (ncases=7201, p = 2.2 x 10-29), less so with 
ER+/PR+/HER2+ cases (ncases=996, p=5.5x10-4), and no association was observed with 
triple negative breast cancer (ncases=1480, p=0.841) or ER-/PR-/HER2+ breast cancer 
(ncases=627, p=0.396). A case-only comparison of HER2 status was carried out within 
ER+/PR+ and ER-/PR- groups, and neither showed any association (p=0.23 and 0.15, 
respectively). 
In the present study, a case-only GWAS approach was used to study differences in the 
distribution of variants between breast cancer cases in a large, multi-center study with 
centralized data collection and handling, the SIGNAL/PHARE case-cohorts 
(NCT00381901/RECF1098).  
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Results  
Genotype data was generated from 9365 SIGNAL/PHARE participants. All subjects had 
greater than 95% genotyping success rate. 26 pairs of individuals were identified with 
Identity by State (IBS) > 30%, with the subject having the most complete genotype data 
from each pair retained for analyses. 551 further individuals were excluded from the 
present study due to PCA analyses. Finally, 61 subjects with missing clinical data were 
excluded.  A total of 8727 patients including 2516 patients with ER- breast cancer were 
analyzed. Furthermore, 5452 patients had HER2-negative breast cancer, of which 1185 
were ER-.  
The search for variants associated with ER status showed only one region with a highly 
significant association, corresponding to FGFR2 (best p-value for rs3135718 p-
value=6.0x10-12, Figure 1). Restricting our analyses to HER2-negative cases found that 
associations between variants at the FGFR2 locus remained significant at the genome-wide 
level (best p-value for rs3135724 = 5.2x10-11, Figure 2). Among HER2-positive tumors, the 
lowest p-value in the FGFR2 locus for the association with ER status was found for 
rs2981578 (p = 3.3x10-4 Table 1). The four variants in Table 1 were chosen to highlight the 
difference in associations between HER2+ and HER2- patients. Despite the smaller sample 
size among HER2-positive cases, this study has nearly 100% power to detect a per-allele OR 
=1.8 as observed among the HER2-negative tumors, and greater than 80% power to detect a 
per-allele OR ≈ 1.3. The observed direction of the association was consistent with 
observations in prior case-control studies, with for example the C allele of rs3135718 being 
more frequently reported among women with ER+ tumors.  
As mentioned previously, variants in the FGFR2 locus were the first identified via GWAS 
with respect to breast cancer risk. The most recent fine-mapping effort of the FGFR2 locus 
explored functional variants, and identified three separate independent sets of correlated 
highly associated variants (ICHAVs [18]). In the present analyses restricted to HER2-
negative tumors, rs3135724 was the SNP with the strongest association for ER status. 
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These data included rs2981579 and rs2981578, from ICHAVs 1 and 3 respectively (Table 1). 
Unfortunately, rs45631563 from ICHAV 2 was not included, and no SNPs showed significant 
linkage disequilibrium with this marker in the current 1000 genomes data 
(http://1000genomes.org accessed July 8, 2015). Therefore additional analyses were 
carried out including rs3135724, rs2981579, and rs2981578 in the same logistic regression 
model. In our analyses of HER2- breast cancer, we found no evidence for independent 
association between these variants and tumor ER status (data not shown).  
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Discussion  
The identification of variants associated with specific molecular subtypes of breast cancer 
was a primary aim of the prospective SIGNAL/PHARE cohort. In this high-powered GWAS 
performed in a case-cohort of breast cancer patients with detailed clinical data, further 
information with respect to variants in the FGFR2 locus and their influence on breast cancer 
were provided, particularly regarding tumor ER status. In addition, the association between 
variants in FGFR2 and ER status in breast cancer was stronger among patients with HER2- 
tumors. While not including an independent validation set is a drawback of our analyses, 
the large sample size allowed us to have sufficient power to fully define this association, and 
the p-values obtained were well below empirical estimations of significance thresholds 
(1.48x10-7) as well as the generic GWAS significance threshold of 5x10-8.   
Our hypothesis is that genetic variants that are associated with molecular subtypes will 
provide novel insights regarding disease etiology, and may lead to further developments 
regarding disease prevention and treatment. As our main focus was the construction of a 
clinical cohort, we have focused on collecting information with respect to histo-pathology 
and treatments, and patient follow-up. Therefore, we have not collected detailed 
information regarding epidemiological data such as body-mass index, reproductive history 
and menopausal status, or family history/BRCA mutations. The participants have been 
given a self-administered questionnaire with some of these variables, but as this 
questionnaire was administered after cancer diagnosis, we have chosen to not exploit these 
data at this time. 
We have focused on the FGFR2 locus, which showed the strongest association with ER 
status, particularly among HER- breast cancer patients. There is growing evidence that 
genetic variants may be more strongly associated with specific breast cancer subtypes. For 
the most part, these analyses are extensions of current prospective cohort and case-control 
analyses. For example, recent analyses by Michailidou et al. [3] included stratification by 
estrogen receptor status for the 77 variants included in their polygenic risk score. A number 
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of these variants showed differential associations with respect to estrogen receptor status. 
However as the authors state in their discussion, the number of estrogen receptor negative 
cases made accurately determining risk estimates difficult for this cancer subtype.Future 
analyses in our case-cohort will investigate other variants previously shown to influence 
breast cancer subtype. 
A potential limitation of our study is the use of an internal imputation process, as opposed 
to imputing to the commonly used 1000 Genomes data or the Michigan Imputation Server. 
As mentioned previously, this was our original study design prior to the availability of these 
resources. We have continued with this approach in order to avoid any potential population 
differences with respect to linkage disequilibrium between our population of French breast 
cancer cases and the populations that provided data for publicly available resources. This 
approach leads to a lower number of variants on the absolute scale, meaning that we may 
be unable to detect any additional variants not captured through genotyping with the 
Illumina Omni5, which captures over 80% of common variants among Caucasian 
populations, and strict quality filtering of data (See Methods section). 
For aspects of response to treatment, SIGNAL/PHARE has not yet accrued enough follow-up 
to fully explore the implication of variants on patient’s outcome. This will be of course an 
obvious next step of our analyses, particularly as pertains to response to hormone therapy 
and FGFR2 variants in ER+/HER- breast cancer patients.  
In conclusion, we further refine the influence of variants in the FGFR2 locus with respect to 
molecular characteristics of breast tumors, in that they are more strongly associated with 
estrogen receptor status among cancers without amplification of the HER2 gene.  
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Methods  
PHARE was a randomized phase 3 clinical trial comparing 6- and 12-month trastuzumab 
adjuvant exposure [15], which included a subset of 1,430 HER2-positive breast cancer cases 
with DNA available for GWAS analyses. SIGNAL was a prospective cohort specifically 
designed for GWAS analyses of 8,406 early breast cancer patients, enrolled at the time of 
the adjuvant chemotherapy from June 2009 to December 2013. The combined data set, the 
PHARE/SIGNAL study, included 9,365 breast cancer patients. Clinical and pathological 
characteristics were prospectively collected using standardized forms, and centralized at 
the French National Cancer Institute (INCa). For both studies, patients provided blood 
samples that were centralized at the Centre d’Etude du PolymorphismeHumain (CEPH) in 
Paris, France, for DNA extraction using standard protocols. Genotyping was carried out at 
the Centre National de Génotypage (CNG) in Evry, France.  
The original study plan called for a two-staged genotyping strategy using only study 
participants. This approach aimed at reducing the potential that population structure in 
French breast cancer cases would influence imputation, while maximizing the proportion of 
the genome covered. Briefly, all cases were genotyped using the IlluminaHumanCoreExome 
chip set, composed of over 264000 variants for a “GWAS Backbone” and over 244000 
“exome-centered” variants. Variants were filtered based on completion rates (<95% SNP 
success, N = 8122), departure from Hardy-Weinberg Equilibrium (HWE p<0.001, N = 
20357), and low minor allele frequency (MAF<0.001, N=200628). Principal Components 
Analysis (PCA) and k-means were then used to characterize the ancestry of the participants 
and only the main cluster of European individuals was included in the present analysis, to 
reduce risk of population stratification (See Figure S1). A random subset of 1449 
individuals from the main “European” cluster was selected for genotyping using the 
Illumina Omni5 chip set, composed of over 4M variants (See Figure S1). Complete (SNP 
success = 100%, N=2049173) Omni5 data were then filtered using similar cutoffs as the 
HumanCoreExome data, specifically HWE (p<0.001, N=91018) were then used to impute 
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missing genotypes from the remaining subjects genotyped using the HumanCoreExome 
array. SNPs with imputation quality score < 30% were excluded from analyses (N=783416), 
and finally variants with a MAF < 0.01 were excluded (N=82847). A total of 914144 SNPs 
were included in the GWAS analyses. Standard GWAS logistic regressions were carried out 
using the ProbABEL package [16]. Age at diagnosis and the first two principal components 
were included in regression analyses. 
Genome-wide significance levels were estimated using the effective number of tests based 
on linkage disequilibrium between all markers used in our population through the SimpleM 
function in R [17]. The number of effective markers is estimated at 345906, corresponding 
to a Bonferroni-corrected p-value threshold of 1.48x10-7.  
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Table 1. Selected variants at the FGFR2 locus and ER status among breast cancer cases 
 
    Overall HER2+ HER2- 
SNP 
I/G* (Rsq, 
Quality) OR (95% CI) p OR (95% CI) p OR (95% CI) p 
rs3135718 I (0.64, 0.89) 1.33 (1.23 - 1.45 6.0x10-12 1.19 (1.04 - 1.35) 7.9x10-3 1.47 (1.30 - 1.64) 2.0x10-10 
rs3135724 I (0.41, 0.84) 1.51 (1.33 - 1.69) 8.1x10-11 1.18 (0.97 - 1.41) 9.3x10-2 1.79 (1.49 - 2.13) 5.2x10-11 
rs2981578 G (NA, NA) 1.24 (1.16-1.32) 3.5x10-10 1.20 (1.09-1.33) 3.3x10-4 1.26 (1.14-1.38) 1.7x10-6 
rs2981579 G (NA, NA) 1.25 (1.16 - 1.33) 5.5x10-11 1.15 (1.03 - 1.27) 9.2x10-3 1.33 (1.20 - 1.47) 2.1x10-9 
* Imputed (I) or genotyped (G). Values reported from MACH output 
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 1 
Figure 1. Manhattan plot of associations between SNPs and ER status overall. 2 
P-values from logistic regression comparing estrogen receptor positive cases to estrogen 3 
receptor negative cases, controlling for age at diagnosis and first two principal components, 4 
are shown. rs3135718 on chromosome 10 at the FGFR2 locus shows the strongest 5 
association. 914144 SNPs were included in these analyses, with 6211 ER+ and 2516 ER- 6 
cases. The red horizontal line corresponds to the empirical significance threshold of 7 
1.48x10-7, while the blue horizontal line corresponds to an arbitrary level of 1.0x10-5. The 8 
inflation factor (λ) for these analyses is 1.02.  9 
Figure 2. Manhattan plot of associations between SNPs and ER status restricted to HER2- 10 
cases.  11 
P-values from logistic regression comparing estrogen receptor positive cases to estrogen 12 
receptor negative cases restricted to HER2- cases, controlling for age at diagnosis and first 13 
two principal components, are shown. rs2981578 on chromosome 10 at the FGFR2 locus 14 
shows the strongest association. The same 914144 SNPs were included in these analyses, 15 
with 4267 HER2-/ER+ and 1185 HER2-/ER- cases. The red horizontal line corresponds to 16 
the empirical significance threshold of 1.48x10-7, while the blue horizontal line corresponds 17 
to an arbitrary level of 1.0x10-5. The inflation factor (λ) for these analyses is 1.02.  18 
  19 
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Supplementary Figure 1: Locuszoom plot of chromosome 10 around the FGFR2 locus. Circles 
represent imputed SNPs, diamonds represent genotyped SNPs. Observed p-value is plotted 
along the left Y axis, recombination rate along the right Y axis. Shading from purple to yellow 
in filled shapes represents linkage disequilibrium with the highlighted SNP, in this case 
rs3135718. 
